BR112018076821A2 - derivados de ftalazina como inibidores de parp1, parp2 e/ou tubulina úteis para o tratamento contra câncer - Google Patents

derivados de ftalazina como inibidores de parp1, parp2 e/ou tubulina úteis para o tratamento contra câncer

Info

Publication number
BR112018076821A2
BR112018076821A2 BR112018076821-9A BR112018076821A BR112018076821A2 BR 112018076821 A2 BR112018076821 A2 BR 112018076821A2 BR 112018076821 A BR112018076821 A BR 112018076821A BR 112018076821 A2 BR112018076821 A2 BR 112018076821A2
Authority
BR
Brazil
Prior art keywords
parp2
parp1
cancer treatment
tubulin inhibitors
inhibitors useful
Prior art date
Application number
BR112018076821-9A
Other languages
English (en)
Inventor
Tsang Tsze
J. Peto Csaba
M. Jablons David
Lemjabbar-Alaoui Hassan
Original Assignee
The Regents Of The University Of California
Atlasmedx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California, Atlasmedx, Inc. filed Critical The Regents Of The University Of California
Publication of BR112018076821A2 publication Critical patent/BR112018076821A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

o pedido se refere a derivados de fórmula (i) que são inibidores de parp1, parp2 e/ou tubulina e, desse modo, úteis para o tratamento de câncer. além disso, são reveladas formulações farmacêuticas que contêm tais compostos, bem como combinações desses compostos com pelo menos um agente terapêutico adicional.
BR112018076821-9A 2016-06-24 2017-06-23 derivados de ftalazina como inibidores de parp1, parp2 e/ou tubulina úteis para o tratamento contra câncer BR112018076821A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662354449P 2016-06-24 2016-06-24
US62/354,449 2016-06-24
US201662426095P 2016-11-23 2016-11-23
US62/426,095 2016-11-23
PCT/US2017/039119 WO2017223516A1 (en) 2016-06-24 2017-06-23 Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer

Publications (1)

Publication Number Publication Date
BR112018076821A2 true BR112018076821A2 (pt) 2019-04-02

Family

ID=59297390

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018076821-9A BR112018076821A2 (pt) 2016-06-24 2017-06-23 derivados de ftalazina como inibidores de parp1, parp2 e/ou tubulina úteis para o tratamento contra câncer

Country Status (16)

Country Link
US (3) US11072600B2 (pt)
EP (1) EP3475272B1 (pt)
JP (2) JP7033588B2 (pt)
KR (1) KR102494294B1 (pt)
CN (1) CN109843874B (pt)
AU (1) AU2017280334C1 (pt)
BR (1) BR112018076821A2 (pt)
CA (1) CA3029004A1 (pt)
ES (1) ES2964531T3 (pt)
IL (1) IL263917B (pt)
MX (2) MX2018015893A (pt)
PL (1) PL3475272T3 (pt)
PT (1) PT3475272T (pt)
SG (1) SG11201811393WA (pt)
WO (1) WO2017223516A1 (pt)
ZA (2) ZA201808562B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10562886B2 (en) 2015-05-21 2020-02-18 The Regents Of The University Of California Anti-cancer compounds
CA3043549C (en) * 2015-11-30 2023-11-21 Children's Medical Center Corporation Compounds for treating proliferative diseases
ES2964531T3 (es) 2016-06-24 2024-04-08 Univ California Derivados de ftalazina como inhibidores de PARP1, PARP2 y/o tubulina útiles para el tratamiento del cáncer
CN111936143A (zh) 2018-04-05 2020-11-13 诺维嘉研究公司 用于治疗癌症的微管蛋白聚合抑制剂和聚(adp-核糖)聚合酶(parp)抑制剂的新型联用药品
CN112574122B (zh) * 2019-09-27 2024-05-31 上海天慈国际药业有限公司 一种奥拉帕尼关键中间体的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3401171A (en) 1966-03-11 1968-09-10 Smithkline Corp 2-amidobenzimidazoles
SU1019810A1 (ru) 1981-07-28 1991-04-07 Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского Метиловый эфир 5(6)-[1-(2Н)-фталазинонил-4]-1Н-бензимидазолил-2-карбаминовой кислоты, обладающий антигельминтной активностью
SU1218649A1 (ru) 1984-09-19 1991-04-30 Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского Способ получени метилового эфира 5(6)-[1(2Н)-фталазинонил-4-]-1Н-бензимидазолил-2-карбаминовой кислоты формулы
EP1060166A1 (de) 1998-02-03 2000-12-20 Boehringer Ingelheim Pharma KG 5-gliedrige benzokondensierte heterocyclen als antithrombotika
AU3076700A (en) 1999-01-26 2000-08-18 Ono Pharmaceutical Co. Ltd. 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient
DE19907813A1 (de) 1999-02-24 2000-08-31 Boehringer Ingelheim Pharma Substituierte bicyclische Heterocyclen, deren Herstellung und deren Verwendung als Arzneimittel
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
EP1330442B1 (en) 2000-10-30 2011-01-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
AR042956A1 (es) 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
EP1751124A4 (en) 2004-05-07 2010-04-14 Exelixis Inc RAF MODULATORS AND METHODS OF USE
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
CN101291928A (zh) * 2005-10-19 2008-10-22 库多斯药物有限公司 4-杂芳甲基取代的酞嗪酮衍生物
TWI404716B (zh) 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
US20080280910A1 (en) * 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
US8889866B2 (en) * 2008-03-27 2014-11-18 Janssen Pharmaceutica, Nv Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors
US9285378B2 (en) 2010-01-29 2016-03-15 Metanomics Gmbh Means and methods for diagnosing heart failure in a subject
CN102372706A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
EP2714703B1 (en) 2011-05-31 2021-03-10 Newgen Therapeutics, Inc. Tricyclic inhibitors of poly(adp-ribose)polymerase
KR101546743B1 (ko) * 2012-01-16 2015-08-24 한국과학기술원 인돌 유도체 화합물, 이를 포함하는 Ａｂｌ 키나제 저해제 조성물 및 이상세포 성장 질환의 예방 및 치료용 약학 조성물
BR112015012425A2 (pt) * 2012-12-31 2017-07-11 Cadila Healthcare Ltd composto, composição farmacêutica, método e medicamento para o tratamento de doenças medicadas pela proteína parp-1 e uso do composto
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
ES2964531T3 (es) * 2016-06-24 2024-04-08 Univ California Derivados de ftalazina como inhibidores de PARP1, PARP2 y/o tubulina útiles para el tratamiento del cáncer

Also Published As

Publication number Publication date
US11072600B2 (en) 2021-07-27
US20190352283A1 (en) 2019-11-21
PT3475272T (pt) 2023-12-15
MX2018015893A (es) 2019-08-01
ZA202301066B (en) 2024-05-30
CN109843874B (zh) 2022-05-27
PL3475272T3 (pl) 2024-04-29
ES2964531T3 (es) 2024-04-08
KR20190033534A (ko) 2019-03-29
IL263917B (en) 2022-07-01
MX2021013641A (es) 2022-01-06
EP3475272B1 (en) 2023-09-13
ZA201808562B (en) 2023-12-20
AU2017280334B2 (en) 2021-07-29
WO2017223516A1 (en) 2017-12-28
AU2017280334A1 (en) 2019-01-17
JP7033588B2 (ja) 2022-03-10
KR102494294B1 (ko) 2023-01-31
US20190337928A1 (en) 2019-11-07
CA3029004A1 (en) 2017-12-28
JP2019522681A (ja) 2019-08-15
CN109843874A (zh) 2019-06-04
SG11201811393WA (en) 2019-01-30
EP3475272A1 (en) 2019-05-01
US20220402894A1 (en) 2022-12-22
JP2022037004A (ja) 2022-03-08
AU2017280334C1 (en) 2022-10-20
IL263917A (en) 2019-02-28
US10640493B2 (en) 2020-05-05

Similar Documents

Publication Publication Date Title
BR112018076821A2 (pt) derivados de ftalazina como inibidores de parp1, parp2 e/ou tubulina úteis para o tratamento contra câncer
CL2023000848A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
CO2019008487A2 (es) Compuesto de quinazolina
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112018074395A2 (pt) derivados de pirazol como inibidores de calicreína plasmática
PH12020550901A1 (en) Macrocyclic compounds for treating disease
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
BR112016015818A2 (pt) Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112016029041A8 (pt) uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
MX2016007351A (es) Terapia de combinacion para tratar cancer.
MX2017013142A (es) Terapia combinada para tratar cáncer.
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
GEP20237519B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
BR112015027440A2 (pt) DERIVADO DE [1,2,4]TRIAZOL[4,3-a]PIRIDINA, MÉTODO DE PREPA-RAÇÃO OU APLICAÇÃO MÉDICA DO DERIVADO
BR112016028641A2 (pt) ?método para tratar câncer?
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
MX370270B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
BR112019003533A2 (pt) terapia de combinação com inibidores de glutaminase
BR112017018198A2 (pt) inibição da atividade de olig2
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
BR112021017957A2 (pt) Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]